Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chitodex-based postoperative therapy for chronic rhinosinusitis after endoscopic sinus surgery
ACTRN12617000072314Phase 2Completed
- Sponsor
- The Queen Elizabeth Hospital
- Start
- Nov 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Chitodex, budesonide and mupirocin in chronic rhinosinusitis (CRS) (3 arms), sponsored by The Queen Elizabeth Hospital. Primary endpoints: Eradication of infection, Endoscopic healing and infection score and 1 more. Started Nov 2016; status: completed.
02
Drugs
Chitodexbudesonidemupirocin
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on ACTRN12617000072314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000072314.